HALDOL (haloperidol lactate) by Johnson & Johnson is clinical pharmacology haloperidol is an antipsychotic. Approved for schizophrenia. First approved in 1967.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
HALDOL (haloperidol lactate) is a first-generation antipsychotic approved in 1967 for schizophrenia treatment. It works as a dopamine D2 receptor antagonist in the central nervous system, with minimal activity at other receptor types. The oral concentrate formulation allows flexible dosing for acute and maintenance psychotic disorder management.
As a legacy antipsychotic approaching loss of exclusivity with moderate competitive pressure (30/100), brand teams are likely consolidating and shifting toward lifecycle management and generic transition planning.
CLINICAL PHARMACOLOGY Haloperidol is an antipsychotic. The mechanism of action of haloperidol for the treatment of schizophrenia is unclear. However, its efficacy could be mediated through its activity as an antagonist at central dopamine type 2 receptors. Haloperidol also binds to alpha-1…
Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT
To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
Worked on HALDOL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HALDOL offers limited career growth potential due to LOE-approaching lifecycle status and zero linked job openings. The role focuses on defending market share against generics and managing the transition to a contracted or divested portfolio asset rather than building new capabilities.